Analysts Are Bullish on These Healthcare Stocks: Amgen (AMGN), OncoCyte (OCX)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Amgen (AMGN – Research Report), OncoCyte (OCX – Research Report) and Belite Bio, Inc. ADR (BLTE – Research Report) with bullish sentiments.

Amgen (AMGN)

Jefferies analyst Michael Yee maintained a Buy rating on Amgen today and set a price target of $325.00. The company’s shares closed last Monday at $244.44.

According to TipRanks.com, Yee is a 2-star analyst with an average return of 0.0% and a 47.4% success rate. Yee covers the Healthcare sector, focusing on stocks such as Prometheus Biosciences, Aligos Therapeutics, and Akero Therapeutics.

Currently, the analyst consensus on Amgen is a Hold with an average price target of $253.85.

See Insiders’ Hot Stocks on TipRanks >>

OncoCyte (OCX)

Needham analyst Michael Matson maintained a Buy rating on OncoCyte today and set a price target of $0.45. The company’s shares closed last Monday at $0.32, close to its 52-week low of $0.20.

According to TipRanks.com, Matson is a 3-star analyst with an average return of 0.9% and a 48.4% success rate. Matson covers the Healthcare sector, focusing on stocks such as Axonics Modulation Technologies, Zimmer Biomet Holdings, and Cardiovascular Systems.

Currently, the analyst consensus on OncoCyte is a Moderate Buy with an average price target of $0.48.

Belite Bio, Inc. ADR (BLTE)

Benchmark Co. analyst Bruce Jackson reiterated a Buy rating on Belite Bio, Inc. ADR today and set a price target of $57.00. The company’s shares closed last Monday at $28.51.

According to TipRanks.com, Jackson is a 1-star analyst with an average return of -4.4% and a 39.6% success rate. Jackson covers the Healthcare sector, focusing on stocks such as Harvard Bioscience, Modular Medical, and Staar Surgical.

Belite Bio, Inc. ADR has an analyst consensus of Moderate Buy, with a price target consensus of $57.50, a 91.7% upside from current levels. In a report released today, H.C. Wainwright also reiterated a Buy rating on the stock with a $58.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on AMGN:

• Viridian Therapeutics initiated with a Buy at Stifel
• Nvidia unveils language models, generative AI service to help Life Sciences R&D
• Amgen (NASDAQ:AMGN) to Slash More Jobs in Second Round of Layoffs
• Street Wrap: Today’s Top 15 Upgrades, Downgrades, Initiations
• Wells Fargo upgrades Amgen to Overweight, lowers target to $265